AuthorsO'Connor, James P B
Jayson, Gordon C
Parker, Geoff J M
van Herk, Marcel
Williams, Kaye J
Waterton, John C
AffiliationCRUK and EPSRC Cancer Imaging Centre in Cambridge and Manchester, University of Manchester, Manchester, UK
MetadataShow full item record
AbstractImaging biomarkers (IBs) are integral to the routine management of patients with cancer. IBs used daily in oncology include clinical TNM stage, objective response and left ventricular ejection fraction. Other CT, MRI, PET and ultrasonography biomarkers are used extensively in cancer research and drug development. New IBs need to be established either as useful tools for testing research hypotheses in clinical trials and research studies, or as clinical decision-making tools for use in healthcare, by crossing 'translational gaps' through validation and qualification. Important differences exist between IBs and biospecimen-derived biomarkers and, therefore, the development of IBs requires a tailored 'roadmap'. Recognizing this need, Cancer Research UK (CRUK) and the European Organisation for Research and Treatment of Cancer (EORTC) assembled experts to review, debate and summarize the challenges of IB validation and qualification. This consensus group has produced 14 key recommendations for accelerating the clinical translation of IBs, which highlight the role of parallel (rather than sequential) tracks of technical (assay) validation, biological/clinical validation and assessment of cost-effectiveness; the need for IB standardization and accreditation systems; the need to continually revisit IB precision; an alternative framework for biological/clinical validation of IBs; and the essential requirements for multicentre studies to qualify IBs for clinical use.
CitationImaging biomarker roadmap for cancer studies. 2016, Nat Rev Clin Oncol
JournalNature Reviews. Clinical Oncology
- Considerations for generic oncology FDG-PET/CT protocol preparation in drug development.
- Authors: Hallett WA, Maguire RP, McCarthy TJ, Schmidt ME, Young H
- Issue date: 2007 Nov
- Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer.
- Authors: Miccò M, Vargas HA, Burger IA, Kollmeier MA, Goldman DA, Park KJ, Abu-Rustum NR, Hricak H, Sala E
- Issue date: 2014 Jul
- PET/MRI in pancreatic and periampullary cancer: correlating diffusion-weighted imaging, MR spectroscopy and glucose metabolic activity with clinical stage and prognosis.
- Authors: Chen BB, Tien YW, Chang MC, Cheng MF, Chang YT, Wu CH, Chen XJ, Kuo TC, Yang SH, Shih IL, Lai HS, Shih TT
- Issue date: 2016 Sep
- [<sup>18</sup>F]-Fluorodeoxyglucose Positron Emission Tomography in the Diagnosis, Treatment Stratification, and Monitoring of Patients with Retroperitoneal Fibrosis: A Prospective Clinical Study.
- Authors: Fernando A, Pattison J, Horsfield C, D'Cruz D, Cook G, O'Brien T
- Issue date: 2017 Jun
- Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET)/MRI for Lung Cancer Staging.
- Authors: Ohno Y, Koyama H, Lee HY, Yoshikawa T, Sugimura K
- Issue date: 2016 Jul